Holen Sie sich die Stockscreener-App
23.39
2.86%
0.65
Handel nachbörslich:
23.39
Schlusskurs vom Vortag:
$22.74
Offen:
$22.85
24-Stunden-Volumen:
366.93K
Relative Volume:
0.72
Marktkapitalisierung:
$1.04B
Einnahmen:
$719.89M
Nettoeinkommen (Verlust:
$98.09M
KGV:
11.50
EPS:
2.0334
Netto-Cashflow:
$118.98M
1W Leistung:
+7.20%
1M Leistung:
+14.38%
6M Leistung:
-7.59%
1J Leistung:
-6.89%
1-Tages-Spanne:
$22.75
$23.46
1-Wochen-Bereich:
$21.48
$23.46
52-Wochen-Spanne:
$17.03
$31.26
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, ZTS, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
23.39 | 1.01B | 719.89M | 98.09M | 118.98M | 2.0334 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-12 | Hochstufung | Needham | Hold → Buy |
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
MSN Money - MSN
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Amphastar Pharmaceuticals Faces Downgrade Despite Strong Annual Revenue - HarianBasis.co
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026 - Black Hills Pioneer
Jefferies Downgrades Amphastar Pharmaceuticals (AMPH), Cites Lack of Meaningful Upside Catalysts - Insider Monkey
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do (NASDAQ:AMPH) - Seeking Alpha
After-close Q1 results: Amphastar schedules May 7 investor call - Stock Titan
Are investors undervaluing Amphastar Pharmaceuticals (AMPH) right now? - MSN
Amphastar outlines key launches and product growth drivers for 2025 - MSN
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance Australia
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) to Release Earnings on Wednesday - MarketBeat
Do options traders know something about Amphastar Pharmaceuticals stock we don't? - MSN
AMPH Price Today: Amphastar Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Amphastar reports FDA approval for teriparatide injection - MSN
Boston Trust Walden Corp Reduces Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals Downgrade: Stock Falls After Analyst MoveNews and Statistics - IndexBox
Jefferies downgrades Amphastar Pharmaceuticals (AMPH) - MSN
Why Amphastar Pharmaceuticals (AMPH) Shares Are Sliding Today - Yahoo Finance
Amphastar Pharmaceuticals (AMPH): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Down 7.4%Time to Sell? - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns Hold Rating from Jefferies Financial Group - MarketBeat
Why (AMPH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Amphastar (AMPH) Stock Market Order (Bullish Sentiment) 2026-04-18Retail Trader Ideas - Xã Thanh Hà
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know - Yahoo Finance
More Than 81,000 Critical Allergy Medications Recalled Nationwide - The Healthy @Reader's Digest
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Amphastar Pharmaceuticals Highlights Baqsimi Milestones, Primatene Growth at Needham Conference - MarketBeat
AMPH: Baqsimi and Primatene Mist drive growth, with new launches and disciplined BD fueling expansion - TradingView
Amphastar Pharmaceuticals, Inc. ($AMPH) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Amphastar Pharmaceuticals, Inc. SEC Filing - Stock Titan
Amphastar (NASDAQ: AMPH) outlines 2026 virtual meeting, director and pay votes - Stock Titan
Amphastar Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
How The Story Is Shifting For Amphastar Pharmaceuticals (AMPH) After Guidance Cut And New Launches - Yahoo Finance
AMPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Barclays Lowers Price Target for Amphastar Pharma (AMPH) | AMPH Stock News - GuruFocus
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Lowered to $23.00 at Barclays - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Rating of "Hold" by Brokerages - MarketBeat
Understanding Momentum Shifts in (AMPH) - Stock Traders Daily
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference - ACCESS Newswire
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):